Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: A preliminary report

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Namura, Kazuhiro ^a   Minamimoto, Ryogo ^a   Yao, Masahiro ^a,d   Makiyama, Kazuhide ^a   Murakami, Takayuki ^a   Sano, Futoshi ^a   Hayashi, Narihiko ^a   Tateishi, Ukihide ^a   Ishigaki, Hanako ^b   Kishida, Takeshi ^b   Miura, Takeshi ^b   Kobayashi, Kazuki ^c   Noguchi, Sumio ^c   Inoue, Tomio ^a,d   Kubota, Yoshinobu ^a,d   Nakaigawa, Noboru ^a,d  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

^c YOKOSUKA KYOSAI HOSPITAL   (Japan)

^d YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG SCREENING; DRUG TUMOR LEVEL; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY SCINTISCANNING; LIVER METASTASIS; LUNG METASTASIS; MALE; PROGNOSIS; SURVIVAL TIME; TUMOR VOLUME; CANCER STAGING; EVALUATION; JAPAN; KAPLAN MEIER METHOD; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RADIOGRAPHY; SCINTISCANNING; TIME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78649562365     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-667     Document Type: Article

References (26)

1. Chow WH, Devesa SS, Warren JL, Fraumeni JF. Rising incidence of renal cell carcinoma in the United States. JAMA 1999, 281:1628-31. 10.1001/jama.281.17.1628, 10235157.
2. Linehan WM, Walther MM, Alexander RB, Rosenberg SA. Adoptive immunotherapy of renal cell carcinoma.:studies from the Surgery Branch, National Cancer Institute. Semin Urol 1993, 11:41-3.
3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol ClinNorth Am 2003, 30:843-852.
4. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996, 335:865-75. 10.1056/NEJM199609193351207, 8778606.
5. Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T, Hoshi S, Nagao K, Yamamoto S, Sugimura I, Uemura H, Koga S, Takahashi M, Ito F, Ozono S, Terachi T, Naito S, Tomita Y. Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients. Eur Urol 2009, 57:317-26. 10.1016/j.eururo.2008.12.026, 19136199.
6. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005, 23:133-141. (23), 10.1200/JCO.2005.03.206, 15625368.
7. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003, 21:3127-3132. 10.1200/JCO.2003.02.122, 2275327, 12915604.
8. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma: Groupe Français D'Immunotherapie. N Engl J Med 1998, 338:1272-8. 10.1056/NEJM199804303381805, 9562581.
9. Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, Sevin E, Caty A, Escudier B, . For The French Immunotherapy Intergroup Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: Results of a randomized controlled trial. Cancer 2007, 110:2468-2477. 10.1002/cncr.23056, 17932908, For The French Immunotherapy Intergroup.
10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007, 356:115-124. 10.1056/NEJMoa065044, 17215529.
11. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, . TARGET Study Group Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med 2007, 356:125-134. 10.1056/NEJMoa060655, 17215530, TARGET Study Group.
12. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, . Global ARCC Trial Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22):2271-81. 10.1056/NEJMoa066838, 17538086, Global ARCC Trial.
13. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, . RECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372(9637):449-56. 10.1016/S0140-6736(08)61039-9, 18653228, RECORD-1 Study Group.
14. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-40.
15. National Comprehensive Cancer Network NCCN Clinical Practice Guideline in Oncology: Kidney Cancer V.1. 2011, National Comprehensive Cancer Network., http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
16. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer oatients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 2004, 59:1295-3000. 10.1016/j.ijrobp.2003.12.039, 15275712.
17. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, Rusch V. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004, 22:3255-60. 10.1200/JCO.2004.11.109, 15310769.
18. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD. [18F] fluorodeoxyglucose uptake by positron emission tomographypredicts outcome of non-small-cell lung cancer. J Clin Oncol 2005, 23:1136-43. 10.1200/JCO.2005.06.129, 15718309.
19. Lee YY, Choi CH, Kim CJ, Kang H, Kim TJ, Lee JW, Lee JH, Bae DS, Kim BG. The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for eary cervical cancer: Preliminary results. Gynecol Oncol 2009, 115:65-68. 10.1016/j.ygyno.2009.06.022, 19604567.
20. Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F, Sobrio F, Bouvard G, Agostini D. Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 2003, 1236-45. 10.1007/s00259-003-1211-4, 12845486.
21. Kang DE, White RL, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004, 171:1806-9. 10.1097/01.ju.0000120241.50061.e4, 15076281.
22. Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, Mekhail TM, Olencki TE, Elson P, Bukowski RM. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003, 21:3995-4000. 10.1200/JCO.2003.04.073, 14581422.
23. Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int 2009, 103:615-9. 10.1111/j.1464-410X.2008.08150.x, 19007371.
24. Lyrdal D, Boijsen M, Suurküla M, Lundstam S, Stierner U. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun 2009, 30:519-24. 10.1097/MNM.0b013e32832cc220, 19522059.
25. Vercellino L, Bousquet G, Baillet G, Barré E, Mathieu O, Just PA, Desgrandchamps F, Misset JL, Hindié E, Moretti JL. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm 2009, 24:137-44. 10.1089/cbr.2008.0527, 19243256.
26. Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006, 24:1997-2005. 10.1200/JCO.2005.03.9594, 16648500.